ID | 1003 |
Name of the vaccine | Vaxelis |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 6 weeks to 4 years |
Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine (DTaP vaccine). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2018 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | 3-doses at 2, 4 and 6 months of age. |
Mechanism of action | Serum diphtheria antitoxin level of 1 IU/ml provides long-term protection. |
Route of administration | Intramuscular |
Indications | Prevents diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b. |
Export | Distributed by - Merck Sharp & Dohme Corp and Sanofi Pasteur Inc, USA |
Approval | US FDA |
Adjuvant | Aluminium salts |
Repurposing | Also for tetanus, pertussis, polio, Hib and hepatitis B. |
Side effects of vaccine | Irritability,crying ,injection site pain,erythema and swelling, somnolence,decreased appetite, fever and vomiting. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/119465/download |
Other name | NA |
Additional Links | NA
|